Astrazeneca annual total debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Total Debt Growth & History (AZN)
Astrazeneca's total debt was $31.43B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $31.43B | −$322.0M | −1.01% |
| 2024 | 2024-12-31 | $31.75B | $2.00B | +6.71% |
| 2023 | 2023-12-31 | $29.75B | −$435.0M | −1.44% |
| 2022 | 2022-12-31 | $30.18B | −$1.58B | −4.98% |
| 2021 | 2021-12-31 | $31.77B | $10.71B | +50.84% |
| 2020 | 2020-12-31 | $21.06B | $2.16B | +11.42% |
| 2019 | 2019-12-31 | $18.90B | −$211.0M | −1.10% |
| 2018 | 2018-12-31 | $19.11B | $1.31B | +7.33% |
| 2017 | 2017-12-31 | $17.81B | $999.0M | +5.94% |
| 2016 | 2016-12-31 | $16.81B | $1.75B | +11.66% |
| 2015 | 2015-12-31 | $15.05B | — | — |
Astrazeneca quarterly total debt
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $32.24B | −$2.23B | −6.48% |
| Q1 2026 | 2026-03-31 | $33.92B | — | — |
| Q4 2025 | 2025-12-31 | $31.43B | −$322.0M | −1.01% |
| Q3 2025 | 2025-09-30 | $32.63B | — | — |
| Q2 2025 | 2025-06-30 | $34.47B | −$302.0M | −0.87% |
| Q4 2024 | 2024-12-31 | $31.75B | $2.00B | +6.71% |
| Q2 2024 | 2024-06-30 | $34.77B | $3.98B | +12.94% |
| Q4 2023 | 2023-12-31 | $29.75B | −$435.0M | −1.44% |
| Q2 2023 | 2023-06-30 | $30.79B | $358.0M | +1.18% |
| Q4 2022 | 2022-12-31 | $30.18B | −$1.58B | −4.98% |
| Q2 2022 | 2022-06-30 | $30.43B | $2.25B | +7.98% |
| Q4 2021 | 2021-12-31 | $31.77B | $10.71B | +50.84% |
| Q2 2021 | 2021-06-30 | $28.18B | $7.80B | +38.26% |
| Q4 2020 | 2020-12-31 | $21.06B | $2.16B | +11.42% |
| Q2 2020 | 2020-06-30 | $20.39B | −$38.0M | −0.19% |
| Q4 2019 | 2019-12-31 | $18.90B | −$211.0M | −1.10% |
| Q2 2019 | 2019-06-30 | $20.42B | $757.0M | +3.85% |
| Q4 2018 | 2018-12-31 | $19.11B | $1.31B | +7.33% |
| Q2 2018 | 2018-06-30 | $19.67B | — | — |
| Q4 2017 | 2017-12-31 | $17.81B | — | — |
Astrazeneca total debt trends
Over the last five fiscal years, Astrazeneca's total debt increased from $21.06B to $31.43B, a change of $10.36B. The latest reported quarter, Q2 2026, shows $32.24B.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...